心血管治療市場規模、佔有率、成長分析，按藥物類型、疾病適應症、給藥途徑、分銷管道、地區分類 - 按行業預測，2024-2031

2022年全球心血管藥物市場規模為1483億美元，從2023年的1543億美元成長到2031年的2090億美元，預測期內（2024-2031年）複合年成長率為3.9，預計將成長3.9% 。

由於高血壓盛行率和心血管疾病盛行率不斷上升，心血管疾病藥物市場正在經歷顯著成長，特別是在工作日程要求較高的新興國家的年輕專業中。久坐的生活方式和不良的飲食習慣導致心血管疾病的發生率增加，促使相關藥物的銷售量激增。此外，人口趨勢顯示這些疾病的發病年齡令人不安地下降，進一步推動了市場需求。儘管已開發國家由於可支配收入較高而擁有獲得更多藥品的優勢，但新興國家仍面臨經濟限制和醫療資源意識低下的挑戰。此外，嚴格的醫藥品認證過程和潛在的副作用是市場擴張的障礙，使應對日益嚴重的心血管健康危機變得更加複雜。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特分析與影響
  • 競爭公司之間的敵對關係
  • 替代品的威脅
  • 買方議價能力
  • 新進入者的威脅
  • 供應商的議價能力

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 技術進步
• 監管環境
• 價值鏈分析
• 專利分析
• 案例研究分析
• 專利分析
• 價格分析
• 管道分析
• 疾病流行病學
• PESTEL分析
• 總體經濟指標
• 市場吸引力指數

心血管治療市場規模：依藥物類型及複合年成長率（2024-2031）

• 市場概況
• 抗高血壓藥
• 抗凝血物
• 高血脂症
• 抗血小板藥
• 其他

心血管治療市場規模：依疾病適應症及複合年成長率（2024-2031）

• 市場概況
• 高血壓
• 冠狀動脈疾病
• 高血脂症
• 心律不整
• 其他

心血管治療市場規模：依給藥途徑及複合年成長率（2024-2031）

• 市場概況
• 口服
• 胃腸外的
• 其他

心血管治療市場規模：按分銷管道和複合年成長率（2024-2031）

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

心血管治療市場規模及複合年成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Bristol-Myers Squibb Company
• Bayer AG
• Pfizer Inc.
• Johnson & Johnson
• Novartis AG
• Merck & Co.
• AstraZeneca
• Sanofi SA
• Gilead Sciences, Inc.
• Viatris
• AMGen
• United Therapeutics
• Daiichi Sankyo Co Ltd
• F. Hoffmann-La Roche AG
• Boehringer Ingelheim GmbH
• Abbott Laboratories
• Eli Lilly and Company
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.

結論和建議

Global Cardiovascular Drugs Market size was valued at USD 148.3 billion in 2022 and is poised to grow from USD 154.3 billion in 2023 to USD 209.0 billion by 2031, growing at a CAGR of 3.9% during the forecast period (2024-2031).

The cardiovascular drug market is experiencing significant growth driven by increasing hypertension prevalence and the rising incidence of cardiovascular disorders, particularly among young professionals in developing nations with demanding work schedules. Sedentary lifestyles and poor dietary habits contribute to escalating cardiovascular disease rates, prompting a surge in related drug sales. Additionally, the demographic trend shows a disturbing decrease in the age of onset for these disorders, further propelling market demand. While developed countries benefit from higher disposable incomes that enhance drug accessibility, challenges persist in developing regions due to financial constraints and limited awareness of healthcare resources. Moreover, stringent drug approval processes and potential side effects serve as barriers to market expansion, presenting complexities in addressing the growing cardiovascular health crisis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiovascular Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiovascular Drugs Market Segmental Analysis

Global Cardiovascular Drugs Market is segmented by Drug Type, Disease Indication, Route of Administration, Distribution Channel and region. Based on Drug Type, the market is segmented into Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs, Others. Based on Disease Indication, the market is segmented into Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiovascular Drugs Market

One of the key drivers propelling the Global Cardiovascular Drugs market is the rising prevalence of cardiovascular diseases, which is significantly influenced by sedentary lifestyles. The World Health Organization (WHO) notes that between 60% to 85% of the global population is inactive, with the Centers for Disease Control and Prevention (CDC) reporting approximately 31 million Americans aged 50 and older engaging in minimal physical activity. Additionally, only about 25% of adults in the U.S. meet the recommended levels of exercise. This alarming trend of inactivity contributes to the growing incidence of cardiovascular conditions, subsequently driving demand for cardiovascular medications and treatments.

Restraints in the Global Cardiovascular Drugs Market

One of the key restraints affecting the global cardiovascular drugs market is the shortage of skilled professionals, which hinders effective drug development and patient care. Additionally, the stringent drug approval processes imposed by regulatory authorities can delay the introduction of new therapies, further constraining market growth. Furthermore, the potential side effects associated with certain cardiovascular medications may deter both healthcare providers and patients from utilizing these treatments, leading to limited adoption. These factors collectively create significant challenges that impact the overall expansion and accessibility of cardiovascular drugs in the market.

Market Trends of the Global Cardiovascular Drugs Market

The Global Cardiovascular Drugs market is experiencing robust growth driven by rising obesity and high cholesterol levels, which significantly elevate cardiovascular disease risks. The demand for emergency medications in hospitals highlights a vital growth area, with many patients requiring long-term management for chronic conditions, ensuring consistent revenue streams. The escalating prevalence of hypertension has further fueled the need for blood thinners and antihypertensive drugs. Additionally, increasing life expectancy among the elderly and a concerning rise in cardiovascular diseases among children are propelling market expansion. The chronic nature of hypertensive medications also contributes to sustained demand, reinforcing the market's positive trajectory.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Value Chain Analysis
• Patent Analysis
• Case Study Analysis
• Patent Analysis
• Pricing Analysis
• Pipeline Analysis
• Disease Epidemiology
• PESTEL Analysis
• Macro-Economic Indicators
• Market Attractiveness Index

Global Cardiovascular Drugs Market Size by Drug Type & CAGR (2024-2031)

• Market Overview
• Antihypertensive
• Anticoagulants
• Antihyperlipidemic
• Antiplatelet Drugs
• Others

Global Cardiovascular Drugs Market Size by Disease Indication & CAGR (2024-2031)

• Market Overview
• Hypertension
• Coronary Artery Disease
• Hyperlipidaemia
• Arrhythmia
• Others

Global Cardiovascular Drugs Market Size by Route of Administration & CAGR (2024-2031)

• Market Overview
• Oral
• Parenteral
• Others

Global Cardiovascular Drugs Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Cardiovascular Drugs Market Size & CAGR (2024-2031)

• North America (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Disease Indication, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMGen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation